Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Baxter
Medtronic
McKinsey
Harvard Business School

Last Updated: November 28, 2022

CLINICAL TRIALS PROFILE FOR VISMODEGIB


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Vismodegib

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00636610 ↗ A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer Completed Genentech, Inc. Phase 2 2008-05-01 This was a randomized, placebo-controlled, double-blind study of vismodegib (GDC-0449) added to biochemotherapy standard-of-care regimens for metastatic colorectal cancer (CRC), with treatment until disease progression. Patients received either FOLFOX (FOL=leucovorin calcium [folinic acid], F=fluorouracil, OX=oxaliplatin) or FOLFIRI (FOL=leucovorin calcium [folinic acid] F=fluorouracil, IRI=irinotecan hydrochloride) chemotherapy with bevacizumab. The decision of which regimen (FOLFOX or FOLFIRI) to use was made by the treating physician and patient. Patients were randomized to receive vismodegib or placebo and were stratified based on the chemotherapy regimen chosen and whether or not Response Evaluation Criteria in Solid Tumors (RECIST) measurable disease was present at baseline.
NCT00739661 ↗ A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission Completed Genentech, Inc. Phase 2 2008-12-01 The study was a Phase II, randomized, placebo-controlled, double-blind, multicenter clinical trial of vismodegib (GDC-0449) in patients with ovarian cancer in a second or third complete remission. Patients were randomized in a 1:1 ratio to either vismodegib or placebo. Randomization was stratified based on whether their cancer was in a second or third complete remission.
NCT00822458 ↗ GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment Completed National Cancer Institute (NCI) Phase 1 2009-01-01 This phase I trial is studying the side effects and best dose of GDC-0449 in treating young patients with medulloblastoma that is recurrent or did not respond to previous treatment. GDC-0449 may be effective in treating young patients with medulloblastoma.
NCT00833417 ↗ A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma Completed Genentech, Inc. Phase 2 2009-02-01 This was a Phase II, single-arm, two-cohort multicenter clinical trial evaluating the efficacy and safety of vismodegib (GDC-0449) in patients with advanced basal cell carcinoma. All patients received vismodegib until evidence of progression, intolerable toxicities most probably attributable to vismodegib, or withdrawal from the study.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Vismodegib

Condition Name

Condition Name for Vismodegib
Intervention Trials
Basal Cell Carcinoma 15
Carcinoma, Basal Cell 4
Stage IV Pancreatic Cancer 4
Refractory Plasma Cell Myeloma 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Vismodegib
Intervention Trials
Carcinoma 30
Carcinoma, Basal Cell 24
Adenocarcinoma 9
Neoplasms 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Vismodegib

Trials by Country

Trials by Country for Vismodegib
Location Trials
United States 372
Italy 30
Canada 24
France 17
Spain 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Vismodegib
Location Trials
California 26
Texas 19
Michigan 18
New York 18
Pennsylvania 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Vismodegib

Clinical Trial Phase

Clinical Trial Phase for Vismodegib
Clinical Trial Phase Trials
Phase 4 2
Phase 2 49
Phase 1/Phase 2 7
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Vismodegib
Clinical Trial Phase Trials
Completed 38
Recruiting 12
Terminated 11
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Vismodegib

Sponsor Name

Sponsor Name for Vismodegib
Sponsor Trials
Genentech, Inc. 22
National Cancer Institute (NCI) 21
Hoffmann-La Roche 12
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Vismodegib
Sponsor Trials
Other 74
Industry 69
NIH 21
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
AstraZeneca
Boehringer Ingelheim
Express Scripts
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.